JP2003529543A - 置換キラル・アロステリック・ヘモグロビン調節剤 - Google Patents

置換キラル・アロステリック・ヘモグロビン調節剤

Info

Publication number
JP2003529543A
JP2003529543A JP2001518407A JP2001518407A JP2003529543A JP 2003529543 A JP2003529543 A JP 2003529543A JP 2001518407 A JP2001518407 A JP 2001518407A JP 2001518407 A JP2001518407 A JP 2001518407A JP 2003529543 A JP2003529543 A JP 2003529543A
Authority
JP
Japan
Prior art keywords
group
methyl
substituted
alkyl
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001518407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529543A5 (enExample
Inventor
ジェイ． アブラハム，ドナルド
エス． ジョシ，ガジャナン
ジェイ． ホフマン，スティーヴン
グレラ，メリッサ
ダンソ−ダンクワ，リッチモンド
ユセフ，アマル
サフォ，マーティン
カルカーニ，サンジェーヴ
Original Assignee
ヴァージニア コモンウェルス ユニバーシティ
アロス セラピュウティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァージニア コモンウェルス ユニバーシティ, アロス セラピュウティクス，インコーポレーテッド filed Critical ヴァージニア コモンウェルス ユニバーシティ
Publication of JP2003529543A publication Critical patent/JP2003529543A/ja
Publication of JP2003529543A5 publication Critical patent/JP2003529543A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001518407A 1999-08-24 2000-08-23 置換キラル・アロステリック・ヘモグロビン調節剤 Withdrawn JP2003529543A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15035199P 1999-08-24 1999-08-24
US60/150,351 1999-08-24
US17663500P 2000-01-19 2000-01-19
US60/176,635 2000-01-19
PCT/US2000/023029 WO2001014316A1 (en) 1999-08-24 2000-08-23 Substituted chiral allosteric hemoglobin modifiers

Publications (2)

Publication Number Publication Date
JP2003529543A true JP2003529543A (ja) 2003-10-07
JP2003529543A5 JP2003529543A5 (enExample) 2007-11-22

Family

ID=26847566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001518407A Withdrawn JP2003529543A (ja) 1999-08-24 2000-08-23 置換キラル・アロステリック・ヘモグロビン調節剤

Country Status (6)

Country Link
US (3) US6486342B1 (enExample)
EP (1) EP1206442A4 (enExample)
JP (1) JP2003529543A (enExample)
AU (1) AU782881B2 (enExample)
CA (1) CA2384511A1 (enExample)
WO (1) WO2001014316A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123126A1 (ja) * 2006-04-17 2007-11-01 Juridical Foundation Osaka Industrial Promotion Organization 慢性心不全における運動耐容能低下の改善剤
JP2007534691A (ja) * 2004-04-22 2007-11-29 アロス・セラピューティクス・インコーポレーテッド アロステリックヘモグロビン修飾体の組成物および前記組成物の製造法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384511A1 (en) * 1999-08-24 2001-03-01 Virginia Commonwealth University Substituted chiral allosteric hemoglobin modifiers
AU2002238132A1 (en) * 2001-02-23 2002-09-12 Allos Therapeutics, Inc. Methods and reagents to acquire mri signals and images
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
CA2563749A1 (en) * 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
US20070259966A1 (en) * 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
EP3092213B1 (en) * 2013-12-27 2019-10-23 Virginia Commonwealth University Allosteric hemoglobin modifiers with nitric oxide releasing moiety
US10836729B1 (en) 2020-05-04 2020-11-17 King Abdulaziz University Metabolically stable 5-HMF derivatives for the treatment of hypoxia
US11104632B1 (en) 2020-05-12 2021-08-31 King Abdulaziz University Metabolically stable vanillin derivatives for the treatment of hypoxia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5382680A (en) * 1990-12-07 1995-01-17 The Center For Innovative Technology Allosteric hemoglobin modifier compounds
US5248785A (en) * 1990-02-12 1993-09-28 Virginia Commonwealth University Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5591892A (en) * 1990-02-12 1997-01-07 Center For Innovative Technology Allosteric modifiers of hemoglobin
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5648375A (en) * 1990-02-12 1997-07-15 Virginia Commonwealth University Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US5250701A (en) * 1990-02-12 1993-10-05 Center For Innovative Technology Allosteric hemoglobin modifiers which decrease oxygen affinity in blood
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5290803A (en) * 1990-02-12 1994-03-01 The Center Of Innovative Technology Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5661182A (en) * 1990-02-12 1997-08-26 Virginia Commonwealth University Method for lowering oxygen affinity of hemoglobin in redcell suspensions, in whole blood and in vivo
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
JP3394596B2 (ja) * 1994-05-23 2003-04-07 日本テトラパック株式会社 包装容器
FR2733685B1 (fr) * 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
US5525630A (en) * 1995-06-01 1996-06-11 Allos Therapeutics, Inc. Treatment for carbon monoxide poisoning
US5827888A (en) * 1996-10-29 1998-10-27 The Center For Innovative Technology Perinatal treatment of a fetus to avoid oxygen deprivation
CA2384511A1 (en) * 1999-08-24 2001-03-01 Virginia Commonwealth University Substituted chiral allosteric hemoglobin modifiers
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534691A (ja) * 2004-04-22 2007-11-29 アロス・セラピューティクス・インコーポレーテッド アロステリックヘモグロビン修飾体の組成物および前記組成物の製造法
WO2007123126A1 (ja) * 2006-04-17 2007-11-01 Juridical Foundation Osaka Industrial Promotion Organization 慢性心不全における運動耐容能低下の改善剤
JPWO2007123126A1 (ja) * 2006-04-17 2009-09-03 財団法人大阪産業振興機構 慢性心不全における運動耐容能低下の改善剤

Also Published As

Publication number Publication date
AU6796700A (en) 2001-03-19
US6486342B1 (en) 2002-11-26
US20030130523A1 (en) 2003-07-10
US20050154062A1 (en) 2005-07-14
EP1206442A1 (en) 2002-05-22
EP1206442A4 (en) 2004-12-29
US6894185B2 (en) 2005-05-17
CA2384511A1 (en) 2001-03-01
WO2001014316A1 (en) 2001-03-01
AU782881B2 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
US7732470B2 (en) Compositions and methods for the treatment of renal and cardiovascular disease
TAMAI et al. Efficient synthetic method for ethyl (+)-(2S, 3S)-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl) butylcarbamoyl]-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteinases
JP2009521467A (ja) 修飾リジン模倣化合物
JP2003529543A (ja) 置換キラル・アロステリック・ヘモグロビン調節剤
JPH08508027A (ja) 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体
KR20010024220A (ko) 신규한 ｎｐｙ 길항제
CN101817769B (zh) 脲基类肽氨肽酶n抑制剂及其应用
MC1985A1 (fr) Derives d'acides amines
EP0187037A2 (en) Piperidine derivatives, their production and use
Phelps Grella et al. Synthesis and Structure− Activity Relationships of Chiral Allosteric Modifiers of Hemoglobin
EP0533516B1 (fr) Nouveaux composés amidiques des 1-(alcoxybenzyl) pipérazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent
JPS6313433B2 (enExample)
JP2603639B2 (ja) チアゾリジン―４―カルボン酸化合物、その製造方法、この化合物を含有する解熱消炎鎮痛剤および虚血・リパーフュージョン症候群治療薬
JP5493870B2 (ja) ３，８−ジアミノテトラヒドロキノリン誘導体
EP2389356A1 (fr) Nouveaux composes de type azapeptide ou azapeptidomimetrique, inhibiteurs de bcrp et/ou p-gp
BE1001618A4 (fr) Peptides et derives peptidiques, leur preparation et leur utilisation comme medicaments.
JP2000515148A (ja) ２―イミダゾリン―５―オンの調製用中間体
CA2167763A1 (fr) Derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69209892T2 (de) Neue 2-Mercaptomethylen-tetrahydronaphthalin- und -indan-2-carboxamide als Enkephalinaseinhibitoren
CN117164562B (zh) 一种氧代哒嗪类化合物及其制备方法和用途
CN114222732B (zh) 一种尿酸促排剂及其合成方法和其在医药上的应用
EP3994122B1 (fr) N-formylhydroxylamines en tant qu'inhibiteurs de la neprilysine (nep), en particulier en tant qu'inhibiteurs mixtes de l'aminopeptidase n (apn) et de la neprilysine (nep)
WO2019138995A1 (ja) ドライアイ改善剤
CN1534027A (zh) 新的取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
CN101906069A (zh) (s)-2-取代-(3’-乙酰基-2’-吡啶酮-1’-基)乙酸及其制备方法和应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071004

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20071101

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071101

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080319